74447-36-2

Upstream product

• 836-43-1 4-benzyloxybenzyl alcohol 
• 74447-40-8 2-(4-hydroxyphenyl)-1,1-dimethoxyethane 
• 74447-37-3 4-methylsulphonyloxyphenylacetaldehyde 
• 501-94-0 p-hydroxyphenethyl alcohol 
• 124-63-0 methanesulfonyl chloride 
• 74447-41-9 2-(4-benzyloxyphenyl)-1,1-dimethoxyethane 
• 74447-39-5 1,1-dimethoxy-2-(4-methylsulphonyloxyphenyl)ethane 
• 74447-38-4 4-(2-hydroxyethyl)phenyl methanesulfonate 
• 836-42-0 4-benzyloxybenzyl chloride 
• 74447-42-0 2-(4-benzyloxybenzyl)-1,3-dithian 

Downstream Products

• 74447-35-1 1-azido-2-(4-methylsulphonyloxyphenyl)ethane 
• 343870-69-9 ethyl 2-ethoxy-3-[3-methyl-4-(2-{4-[(methylsulfonyl)oxy]phenyl}ethoxy)phenyl]propanoate 
• 218139-08-3 4-[2-(4-formylphenoxy)ethyl]phenyl methanesulfonate 
• 251565-91-0 ethyl (2S)-2-ethoxy-3-[4-(2-{4-[(methylsulfonyl)oxy]phenyl}ethoxy)phenyl]propanoate 
• 74447-38-4 4-(2-hydroxyethyl)phenyl methanesulfonate 
• 1055303-88-2 2-[2-(4-fluoro-phenyl)-ethylsulfanyl]-3-{4-[2-(4-methanesulfonyloxy-phenyl)-ethylsulfanylcarbonyl]-phenyl}-propionic acid 2,2,2-trichloro-ethyl ester 
• 1055303-65-5 thioacetic acid S-[2-(4-methanesulfonyloxy-phenyl)-ethyl] ester 
• 343870-40-6 ethyl 3-[3-[(tert-butoxycarbonyl)amino]-4-(2-{4-[(methylsulfonyl)oxy]phenyl}ethoxy)phenyl]-2-ethoxypropanoate 
• 343870-38-2 ethyl 3-[3-tert-butyl-4-(2-{4-[(methylsulfonyl)oxy]phenyl}ethoxy)phenyl]-2-ethoxypropanoate 
• 343870-36-0 ethyl 3-[3-benzyl-4-({4-[(methylsulfonyl)oxy]phenethyl}oxy)phenyl]-2-ethoxypropanoate 

Relevant academic research and scientific papers

Selective hydrolysis of methanesulfonate esters

The pH dependence of the hydrolysis of 4-{2-[(methylsulfonyl)oxy]ethyI} phenyl methanesulfonate, 1, and two carboxylate esters, ethyl 2(S)-ethoxy-3-(4-hydroxyphenyl)propionate, 2 and (2S)-2-ethoxy-3-[4-(2-{4- [(methylsulfonyl)oxy]phenyl}ethoxy)phenyl]propanoate, 3, has been studied with a view to the selective removal of any remaining 1, following coupling with 2 to generate 3 in water at 95 °C (Scheme 1). It is shown that reduction of pH from that of the reaction conditions (pH ≈ 10) to pH 7-8 has little effect on the hydrolysis of 1, which is dominated by the water rate over this pH range, but reduces the rate of hydrolysis of the carboxylate ester group by 3 orders of magnitude (pH 7). This very strong quantitative difference in the response of the two types of ester group to pH change allows complete removal of 1 at low pH without measurable loss to the product ester, 3. The conclusions should be generally applicable to the removal of potentially genotoxic alkyl esters of methane sulfonic acid in the presence of carboxylic esters and other base-sensitive groups.

CHEMICAL COMPOUNDS 428

Compounds of formula (I): wherein variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are described.

NOVEL COMPOUNDS AS AGONIST FOR PPAR GAMMA AND PPAR ALPHA, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

The present invention relates to novel compounds accelerating the activity of Peroxisome proliferator-activated receptor gamma (PPARγ) and alpha (PPARα), processes of preparing the same, and pharmaceutical compositions containing the same as an active agent.

Comminuted form of(s)-2-ethoxy -3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid

The present invention relates to a reduced particle size form of the compound (S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid, as shown in formula (I), or a pharmaceutically acceptable salt thereof or a solvate of either thereof. The invention also concerns methods of treating one or more conditions associated with Insulin Resistance Syndrome using the reduced particle size form of the compound, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in one or more of said conditions. The invention further concerns pharmaceutical compositions containing the reduced particle size form of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient, as well as processes for the manufacture of the reduced particle size form of the compound, or a pharmaceutically acceptable salt thereof.

Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them

The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.

Thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives

Novel thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives, process for their manufacture, pharmaceutical preparations containing them and the use of the compounds in conditions associated with insulin resistance.